Rezolute Launches Underwritten Stock and Pre-Funded Warrant Offering Days After $400M Shelf
RZLT has more than doubled off its 52-week low of $1.07.
Summary
Rezolute kicked off a Morgan Stanley-led underwritten offering of common stock and pre-funded warrants under its November 5 shelf, with size and pricing still blank in this preliminary supplement.
Updates
· SEC FWP — Rezolute priced the offering at $3.87 per share for 22,040,976 shares plus 3,800,000 pre-funded warrants at $3.869, for about $100 million gross, led by Frazier Life Sciences.
Key Events · Financing and Capital Events · RZLT
-
Underwritten Offering Launched
A preliminary prospectus supplement covers an underwritten offering of common stock and pre-funded warrants, with Morgan Stanley as lead book-running manager.
-
Terms Still Blank
Share count, offering price and net proceeds are left blank in this preliminary supplement, so the raise size and dilution are not yet determinable.
-
Pre-Funded Warrant Structure
Pre-funded warrants are priced at the offering price minus $0.001 with a $0.001 exercise price; they are exercisable immediately and subject to 4.99%/9.99% ownership caps (up to 19.99% at the holder's election).
-
Use of Proceeds
Net proceeds fund ersodetug commercialization preparation plus working capital and general corporate purposes.
Analysis · RZLT · Life Sciences
Rezolute is going to market for equity through a Morgan Stanley-led underwritten offering of common stock and pre-funded warrants, drawing on the $400 million shelf it registered on November 5. Because the supplement is preliminary, share count, offering price and net proceeds are all left blank, so neither the size of the raise nor the resulting dilution can yet be quantified. The timing is the clear signal: the company is seeking cash eight days after reporting $90.0 million in cash against an $18.5 million quarterly net loss, and one day after announcing positive preliminary upLIFT results in tumor HI. As for structure, the pre-funded warrants (offering price minus $0.001, $0.001 strike) let buyers take exposure without triggering ownership thresholds, a common feature of larger institutional placements. Existing holders should expect dilution once final terms are set; the 30-day company and insider lock-up limits near-term selling pressure.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RZLT was trading at $3.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $374.3M. The 52-week trading range was $1.07 to $11.17. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.